Topic: non-Hodgkin lymphoma
Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.
Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Longtime Cowen analyst Eric Schmidt is joining Arie Belldegrun's latest CAR-T startup, Allogene.
Epizyme's lead asset tazemetostat posted promising interim data from a phase 2 trial in follicular lymphoma.
Just 48 hours after filing a $115 million IPO, Forty Seven unveiled the first data for its CD47 antibody at ASCO, pledging moves into phase 2 studies.
Unum revealed more than its IPO goals in its SEC filing: a clinical hold and two patient deaths.
Buried within Swiss major Roche's fourth-quarter financials was the announcement that it was dumping a host of early- and late-stage candidates.
Eureka Therapeutics will advance its T-cell treatment for relapsed and refractory CD19+ non-Hodgkin lymphoma into the clinic.
Phase 2 data presented at ASH 2017 suggests that Roche's high expectations for its antibody-drug conjugate for non-Hodgkin lymphoma could be justified.